Literature DB >> 2721330

Protein binding characteristics of bumetanide.

P C Walker1, N S Berry, D J Edwards.   

Abstract

The association constants (k) and binding capacities (np) of bumetanide were determined in pooled venous blood obtained from adults, venous cord blood of healthy full-term infants, and critically ill neonates using ultrafiltration. Bumetanide was highly bound to plasma proteins (approximately 97%) in all three populations studied. Two classes of binding sites were identified, a high-affinity, low-capacity site with k and np in the order of 10(3) M-1 and 10(-3) M, respectively, and a low-affinity, high-capacity site with k and np in the order of 10(2) M-1 and 10(-2) M, respectively. Binding capacities were similar between the three groups studied and were larger than the 'presumed' therapeutic concentration following intravenous administration of the drug, which is on the order of 10(-6) M (less than or equal to 0.5 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2721330

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  8 in total

1.  Volume regulation in mammalian skeletal muscle: the role of sodium-potassium-chloride cotransporters during exposure to hypertonic solutions.

Authors:  Michael I Lindinger; Matthew Leung; Karin E Trajcevski; Thomas J Hawke
Journal:  J Physiol       Date:  2011-04-11       Impact factor: 5.182

2.  Exercise-induced changes in plasma composition increase erythrocyte Na+,K+-ATPase, but not Na+-K+-2Cl- cotransporter, activity to stimulate net and unidirectional K+ transport in humans.

Authors:  Michael I Lindinger; Simon P Grudzien
Journal:  J Physiol       Date:  2003-10-03       Impact factor: 5.182

3.  Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details.

Authors:  Yehezkel Ben-Ari; Eric Delpire
Journal:  Epilepsia       Date:  2021-02-03       Impact factor: 6.740

Review 4.  Off-Label Use of Bumetanide for Brain Disorders: An Overview.

Authors:  Shivani C Kharod; Seok Kyu Kang; Shilpa D Kadam
Journal:  Front Neurosci       Date:  2019-04-24       Impact factor: 4.677

Review 5.  NKCC1, an Elusive Molecular Target in Brain Development: Making Sense of the Existing Data.

Authors:  Mari A Virtanen; Pavel Uvarov; Christian A Hübner; Kai Kaila
Journal:  Cells       Date:  2020-12-04       Impact factor: 6.600

6.  A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders.

Authors:  Eric Delpire; Yehezkel Ben-Ari
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

Review 7.  Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures.

Authors:  Martin Puskarjov; Kristopher T Kahle; Eva Ruusuvuori; Kai Kaila
Journal:  Epilepsia       Date:  2014-05-06       Impact factor: 5.864

8.  Cerebral influx of Na+ and Cl- as the osmotherapy-mediated rebound response in rats.

Authors:  Eva Kjer Oernbo; Kasper Lykke; Annette Buur Steffensen; Kathrin Töllner; Christina Kruuse; Martin Fredensborg Rath; Wolfgang Löscher; Nanna MacAulay
Journal:  Fluids Barriers CNS       Date:  2018-09-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.